Skip to main content
Lucibel SA logo

Lucibel SA — Investor Relations & Filings

Ticker · ALUCI ISIN · FR0011884378 LEI · 9695009AOETI38F0R646 PA Manufacturing
Filings indexed 137 across all filing types
Latest filing 2022-07-22 Share Issue/Capital Cha…
Country FR France
Listing PA ALUCI

About Lucibel SA

https://www.lucibel.io/en/

Lucibel SA is an innovative group that designs and manufactures new-generation lighting products and solutions based on LED technology. The company specializes in smart lighting that utilizes light for data transmission, interaction, and well-being. Its key innovations include "LiFi by Lucibel," a secure, light-based internet access solution; "VLC by Lucibel," a geolocation and interaction technology using light signals detected by mobile devices; and "Cronos," a circadian lighting system that simulates natural sunlight to enhance concentration and sleep quality. Lucibel serves a wide range of professional markets, including offices, education, healthcare, retail, museums, and industry, offering both standard luminaires and turnkey project solutions through its various entities.

Recent filings

Filing Released Lang Actions
LUCIBEL SECURISE UN FINANCEMENT EN FONDS PROPRES D'UN MONTANT CIBLE DE 1,7 M EUR AVEC NICE AND GREEN
Share Issue/Capital Change Classification · 99% confidence The document announces that Lucibel is securing a financing operation ('LUCIBEL SECURISE UN FINANCEMENT EN FONDS PROPRES D'UN MONTANT CIBLE DE 1,7 M€ AVEC NICE & GREEN'). The financing mechanism involves the issuance of warrants (BSAR - bons de souscription d'actions remboursables) reserved for a specific investor, Nice & Green. This clearly describes an activity related to raising capital, changing the capital structure, or securing new financing. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it details a specific corporate financing event.
2022-07-22 French
RESISTANCE DU CHIFFRE D'AFFAIRES DU 1ER SEMESTRE 2022 ET RAPPEL DE L'EXISTENCE DE BSAR
Earnings Release Classification · 99% confidence The document provides unaudited financial data for the first semester of 2022 (1er semestre 2022), including revenue figures compared to previous periods. It discusses business performance, outlook for the second half of 2022, and includes a reminder about expiring stock warrants (BSAR). The key indicator is the presentation of detailed, period-specific financial results (Chiffre d'affaires) for a period shorter than a year (1st semester). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K), an Earnings Release (ER, which is usually just highlights), or a Call Transcript (CT). The mention of the next publication date for the full 1st semester accounts on October 12, 2022, further confirms this is the preliminary/interim report itself. H1 2022
2022-07-12 French
LUCIBEL ANNONCE SES RÉSULTATS ANNUELS 2021 : Résistance du chiffre d'affaires en dépit d'un contexte de marché compliqué et forte progression du taux de marge brute
Earnings Release Classification · 99% confidence The document is titled 'LUCIBEL ANNONCE SES RÉSULTATS ANNUELS 2021' (Lucibel announces its 2021 annual results) and contains detailed financial tables for the years 2021 and 2020, including Income Statement (Compte de Résultat) and Balance Sheet (Bilan) data. It explicitly discusses annual performance, margins, and future outlook for the full year. Although the data is 'en cours d'audit' (under audit), the comprehensive nature and the focus on the full fiscal year strongly indicate this is the primary annual financial disclosure. Since it is a detailed report covering the full year, it aligns best with the Annual Report category (10-K), even if it is presented as a press release summarizing the findings, as it contains the core financial statements. It is not merely an Earnings Release (ER) which is typically shorter and highlights only key figures, nor is it a quarterly report (IR). The length (over 23k characters) also suggests a comprehensive filing rather than a brief announcement (RPA/RNS). FY 2021
2022-04-12 French
ÉTUDE CLINIQUE SUR LE MASQUE DE BEAUTÉ OVE : MISE EN AVANT D'UNE PERSISTANCE REMARQUABLE DES RESULTATS OBTENUS PENDANT 6 SEMAINES À COMPTER DE L'ARRET DU PROTOCOLE
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and details the results of a clinical study regarding a cosmetic product (OVE beauty mask) and the persistence of its anti-aging effects after treatment cessation. It announces scientific findings and includes contact information for press relations. This type of announcement, which is a general corporate communication about a specific business development (product efficacy study), does not fit neatly into the specific financial filing categories like 10-K, ER, or IR. Since it is a general announcement that doesn't fit the other specific categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory or corporate announcements not covered elsewhere.
2022-03-14 French
2021: année de transition avant la reprise de la croissance en 2022
Earnings Release Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and presents summarized, non-audited financial data for the year 2021, along with commentary on business segments and future outlook for 2022. It explicitly mentions key financial figures (Chiffre d'affaires) and corporate events (BSAR exercise, asset sales, merger). Crucially, it includes a section titled "Prochaines publications" which states: "12 avril 2022 avant bourse : publication des comptes annuels 2021" (April 12, 2022 before market: publication of the 2021 annual accounts). Since this document is a press release summarizing the year's performance but explicitly points to a future date for the full annual accounts publication, it functions as an initial announcement of financial results, often referred to as an Earnings Release (ER) or a preliminary results announcement, rather than the comprehensive Annual Report (10-K) or the full Interim Report (IR). Given the focus on summarizing the past year's performance and providing forward-looking statements immediately preceding the scheduled release of the full annual accounts, the most appropriate classification is Earnings Release (ER). FY 2021
2022-01-27 French
LUCIBEL RÉSULTATS TRÈS POSITIFS DE L'ÉTUDE CLINIQUE SUR LE MASQUE DE BEAUTÉ OVE ET RÉVISION À LA HAUSSE DES PERSPECTIVES DE CROISSANCE DE L'ACTIVITÉ COSMÉTIQUE DE LUCIBEL
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and dated January 13, 2022. It announces "RÉSULTATS TRÈS POSITIFS DE L'ÉTUDE CLINIQUE" (Very Positive Results of the Clinical Study) and revises growth outlooks. This format, focusing on a specific, recent operational/product development (clinical trial results for a cosmetic device) released via a press release, strongly suggests a general corporate announcement rather than a formal regulatory filing like a 10-K, IR, or ER. Since it is a press release announcing positive operational news and outlook revision, it fits best under the general Regulatory Filings category (RNS) as a fallback, or potentially an Earnings Release (ER) if the context implied periodic financial reporting, but the focus here is on a specific product study, not quarterly financials. Given the options, RNS (Regulatory Filings) is the most appropriate general category for a non-standard, non-periodic corporate announcement like this press release, although it is not a formal SEC filing. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal Financial Report (10-K, IR).
2022-01-13 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.